BW
STLNW

Boaz Weinstein’s Starling Oncology Warrant STLNW Stock Holding History

Boaz Weinstein’s Portfolio STLNW Stock Details STLNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-24,464
Closed -$52K – 184
2020
Q3 		$52K Buy
+24,464
New +$40.2K ﹤0.01% 144

Other funds holding STLNW

SRCM
Sage Rock Capital Management New York $22.3M AUM 4.09% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
ECM
Element Capital Management New York $3.2B AUM 29.54% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $62.7B AUM 29.77% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
BI
Bulldog Investors Saddle Brook, New Jersey $455M AUM 2.3% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Boaz Weinstein's STLNW Position: Q4 2020 in Review

Boaz Weinstein sold out of Starling Oncology Warrant (STLNW) in Q4 2020, closing a stake of 24,464 shares — an estimated $52K sold.

Boaz Weinstein first reported a position in STLNW in Q3 2020 and held it in 1 quarter. The position peaked at $52K in Q3 2020. 25 funds tracked by Wall St. Rank hold STLNW as of Q4 2020.

  • Boaz Weinstein reported no remaining Starling Oncology Warrant position as of Q4 2020 after selling out during the quarter.
  • Boaz Weinstein sold 24,464 Starling Oncology Warrant shares in Q4 2020, an estimated $52K.
  • Boaz Weinstein first reported a position in Starling Oncology Warrant in Q3 2020 and held it in 1 quarter.
  • Boaz Weinstein's Starling Oncology Warrant position peaked at $52K in Q3 2020.
  • 25 funds tracked by Wall St. Rank held Starling Oncology Warrant as of Q4 2020.

Based on Saba Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.